Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
The Oncologist · 01.10.2025 · 30 (10)
DOI: 10.1093/oncolo/oyaf323 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 29.09.2025. Verfasst von Tristan L Lim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Cancer Center, Massachusetts General Hospital, Boston, MA 02114, United States. Hauptthemen laut MEDLINE: Uveal Melanoma, Recombinant Fusion Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Mass General Cancer Center's Melanoma Program, Mass General Cancer Center’s Melanoma Program.
Abstract (Originalsprache)
Background
Tebentafusp has significantly improved overall survival in HLA-A*02:01+ metastatic uveal melanoma (mUM) patients even in those with a best objective response of progressive disease. Thus, strategies to maintain tebentafusp therapy are critical. Here, we examine the efficacy and safety of adding concurrent local therapy (CLT) to tebentafusp upon radiological progression with tebentafusp alone. Patients and Methods This multicenter retrospective study included mUM patients treated with tebentafusp and CLT, consisting of extrahepatic soft tissue irradiation and liver-directed therapies (LDTs). Efficacy of target and nontarget sites were assessed per RECIST version 1.1. PFS with tebentafusp alone (PFS1) was compared to that after adding CLTs to tebentafusp upon progression (PFS1+PFS2). ctDNA responses were explored.
Results
Of the 30 eligible patients, 21 (70%) received concurrent LDT, 7 (23%) had extrahepatic irradiation, and 2 (7%) had both. The objective response rate (ORR) was 12% (95% CI, 3-32) for tebentafusp alone and 28% (95% CI, 14-47) after adding CLTs. The disease-control rate with tebentafusp alone was 44% (95% CI, 25-65) vs 63% (95% CI, 44-78) after CLT. Median PFS1 was 5.8 months (95% CI, 2.8-13.4), while median PFS1+PFS2 was 14.8 months (95% CI, 9.2-NA). CLT thereby allowed treatment beyond progression with tebentafusp for approximately 9 months. Two patients (66%) had decreased ctDNA with tebentafusp alone, while 4 (100%) had decreased ctDNA after CLT. There were no treatment discontinuations due to toxicities from tebentafusp with CLT.
Conclusions
CLT with tebentafusp was well-tolerated, extending the duration of tebentafusp benefit in a highly selected mUM population. This merits further studies to assess clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mass General Cancer Center, Massachusetts General Hospital, Boston, MA 02114, United States.
- Department of Interventional Radiology, Massachusetts General Hospital, Boston, MA 02114, United States.
- Memorial Sloan Kettering Cancer Center, New York City, NY 10065, United States.
- Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, United States.
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York City, NY 10032, United States.
- Northwell Health Cancer Institute, New Hyde Park, NY 11042, United States.
ORCID-Profile: Tristan L Lim, Omid Hamid, Ryan J Sullivan
Förderung
- NCI NIH HHS
- Mass General Cancer Center's Melanoma Program
- Mass General Cancer Center’s Melanoma Program
Zitieren
APA
Lim, T. L., Montazeri, K., Wehrenberg-Klee, E., Desilets, A., Seedor, R., Orloff, M., Sato, T., Caplan, M., El-Ashmawy, M., Izar, B., Khan, S., Mehmi, I., Lawless, A., Hong, T. S., Hamid, O., Carvajal, R. D., Shoushtari, A., & Sullivan, R. J. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist, 30(10). https://doi.org/10.1093/oncolo/oyaf323
Vancouver
Lim TL, Montazeri K, Wehrenberg-Klee E, Desilets A, Seedor R, Orloff M, et al. Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 2025;30(10). doi:10.1093/oncolo/oyaf323
BibTeX
@article{Lim2025,
author = {Lim, Tristan L and Montazeri, Kamaneh and Wehrenberg-Klee, Eric and Desilets, Antoine and Seedor, Rino and Orloff, Marlana and Sato, Takami and Caplan, Michael and El-Ashmawy, Mariam and Izar, Benjamin and Khan, Shaheer and Mehmi, Inderjit and Lawless, Aleigha and Hong, Theodore S and Hamid, Omid and Carvajal, Richard D and Shoushtari, Alexander and Sullivan, Ryan J},
title = {Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {10},
doi = {10.1093/oncolo/oyaf323}
}
EUVIMED